Three fast-rising S&P/ASX 200 Index (ASX: XJO) gold stocks released their full-year FY 2026 earnings results this morning.

And investors have responded by bidding all three stocks higher as we head into the Friday lunch hour, despite the 0.2% fall in the ASX 200 at this same time.

Here’s what’s happening.

Ramelius Resources Ltd (ASX: RMS)

Ramelius Resources shares are up 0.8% at time of writing, swapping hands for $3.95 apiece.

That sees this ASX 200 gold stock up 37% since this time last year.

For FY 2026, Ramelius reported a 1% year-on-year increase in revenue to $1.03 billion.

Underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $765 million were down 7%.

On the bottom line, the gold miner reported a 33% year-on-year decline in underlying net profit after tax (NPAT) to $320 million.

Profits and earnings were impacted in part by the lower production volumes associated with the completion of operations at the company’s Edna May project.

Regis Resources Ltd (ASX: RRL)

Regis Resources shares are also attracting attention today after the miner released its FY 2026 results.

Shares in the ASX 200 gold stock are up 3.2%, trading for $8.49 each. That sees the Regis Resources share price up 90% in 12 months.

Over the 12 months, Regis Resource produced 379,050 ounces of gold at an all-in sustaining cost (AISC) of $2,945 per ounce.

The miner sold 373,879 ounces over the year, receiving an average price of $6,283 per ounce.

This saw revenue increase by 43% from FY 2025 to $2.35 billion. And it helped the miner set a new record NPAT of $715 million, up a whopping 181% year on year.

With profits soaring, management declared a fully-franked final dividend of 20 cents per share.

Regis ended the year with cash and bullion holdings of $1.18 billion, up $667 million from the close of FY 2025.

Genesis Minerals Ltd (ASX: GMD)

The third ASX 200 gold stock making moves following the release of its full-year results is Genesis Minerals.

Genesis Minerals shares are up 2%, trading for $8.17 apiece. That puts the share price up 93% since this time last year.

FY 2026 was an eventful period for the miner, with gold production up 33% from FY 2025 to 285,402 ounces. Genesis produced the gold at an AISC of $2,670 per ounce.

And earnings hit a new record high, with the company reporting a 110% lift in EBITDA to $952 million.

Profits surged as well, with underlying NPAT up 147% to $547 million.

And with profits rocketing, the ASX 200 gold stock delivered its first ever dividend, fully franked at 5 cents per share.

Genesis Minerals ended the financial year with cash and equivalents of $520 million, up 81% from last year.

The post 3 ASX 200 gold stocks jumping higher on big news today appeared first on The Motley Fool Australia.

More reading

• Ramelius Resources reports profit drop, expands growth plans in FY26 earnings
• Regis Resources delivers record FY26 profit and dividends
• Genesis Minerals FY26 earnings: profit, growth, maiden dividend
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are tumbling on Friday, falling 8% to $16. That is a sharp reversal after the stock climbed 5% on Thursday following the release of its half-year results.

Despite today’s decline, Telix shares remain up around 42% year to date, although they are down roughly 4% over the past 12 months.

So, why are Telix shares plunging despite another strong set of numbers?

Telix delivers strong first-half growth

On Thursday, Telix reported a 22% year-on-year increase in revenue to US$477 million, tracking towards the upper end of its FY26 guidance. The company’s gross margin improved to 55%, while its Precision Medicine segment delivered an impressive 65% margin.

Adjusted EBITDA jumped 146% to US$52 million, while profit after tax reached US$38 million. That included a US$40 million payment from Regeneron.

Operationally, Precision Medicine remained the key growth engine, with flagship products Illuccix and Gozellix continuing to gain market share.

The biotech company also achieved several important clinical milestones, including completing enrolment for late-stage trials and making regulatory progress across the US, China, Europe, and Japan.

The business is simultaneously expanding its global manufacturing footprint through new and upgraded facilities in Australia, Belgium, Japan, and the US.

Telix shares reaffirmed FY26 revenue and other income guidance of more than US$1 billion, with Research & Development expenditure expected to come in between US$230 million and US$270 million.

Why are Telix shares falling?

One clue for the plummeting Telix share price comes from Bell Potter.

The leading broker was pleased with Telix’s first-half performance, but warned that competition could weigh on revenue later in the year. It said:

1H26 increased by 22% to $477m, dominated by US sales of PSMA imaging agents. FY26 revenue guidance range is unchanged at $950m – $970m with the company guiding to the upper end. We expect the launch of a competitor product (TruVu – Lantheus) will impact 4Q26 revenues, nevertheless, the top end of the guidance is realistic. We do not anticipate a change in guidance irrespective of 3Q26 revenues.

Importantly, Bell Potter now believes Telix shares are approaching fair value. As a result, it has downgraded the stock from buy to hold, while retaining its $19 price target.

That target still represents potential upside of roughly 17% from $16, but the downgrade may be giving investors pause after Telix’s substantial gains this year.

In other words, today’s sell-off may have less to do with disappointing results and more to do with valuation, competition, and expectations for future growth.

The post Telix shares are tumbling. Is the stock finally at fair value? appeared first on The Motley Fool Australia.

More reading

• Why were Telix shares just downgraded?
• 5 things to watch on the ASX 200 on Friday
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
• These are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The analyst team at UBS has been hard at work this week analysing the deluge of profit reports which have come out, and have issued a number of buy recommendations on companies.

I’ve selected three of those which UBS believes will perform particularly well from a share price perspective, which I’ll run through now.

Let’s have a look.

Zip Co Ltd (ASX: ZIP)

Zip on Thursday announced record cash EBTDA of $268.9 million, up 57.9% on the previous year.

The buy now, pay later provider said total transaction volume (TTV) grew to $16.7 billion, up 27.2%, while the number of merchants on its platforms increased 13.8%.  

On the outlook, Chief Executive Officer Cynthia Scott said the company was targeting cash earnings of $340 million in FY27, which would be a 26% increase.

UBS said in a note to clients that the outlook for the current year was better than expected, providing comfort around the defensive qualities of the buy now, pay later business model through slowing economic times.

UBS said:

Whilst macro remains key uncertainty into FY27, we have increased confidence around Zip’s defensive quality and ability to drive customer growth and transaction frequency. Our US TTV growth forecast of +30% in FY27 is comprised of 9% customer growth and 19% TTV/customer growth, which we view achievable.

UBS has a price target on ZIP shares of $4.70 compared to $2.76 currently.

Megaport Ltd (ASX: MP1)

This cloud computing company this week announced FY26 revenue of $312.2 million, up 37%, while EBITDA was up 24% to $77.1 million.

Megaport Chief Executive Officer Michael Reid said:

Our team delivered an exceptional result in FY26. The Network business produced its strongest commercial performance to date, Latitude.sh expanded rapidly following acquisition, and our combined capabilities secured major long-term customer contracts across Compute, Network, and Storage. We have materially increased the scale of the business, broadened the markets we can serve, and created a much larger opportunity. Now our job is to execute against it.

UBS said the net outcome of the results report was “firmly in the positive”, and they are estimating EBITDA of $624 million for Megaport in FY28.

The broker has a price target of $26.40 on Megaport shares, up from $24.20, compared to the current share price of $18.60.

MA Financial Group Ltd (ASX: MAF)

UBS said MA Financial Group delivered an in-line FY26 result, “though we think the share price reaction (+18%) reflects material potential for upside towards new FY29 targets, and a stronger 2H outlook”.

UBS has a price target on MA Financial Group of $10.10 compared to $7.07 currently.

The post 3 ASX shares UBS says will return better than 36% appeared first on The Motley Fool Australia.

More reading

• How high do UBS and Macquarie think Zip shares will go?
• Buy, hold, sell: Fortescue, Northern Star, and Megaport shares
• Here are the top 10 ASX 200 shares today
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Buy, sell, hold: Dexus, APA, Zip shares

Motley Fool contributor Cameron England has positions in Megaport. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport. The Motley Fool Australia has recommended Ma Financial Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.